title: [Effect of cefaclor on guinea pig platelet aggregation in vitro].
abstract: Effects of cefaclor (3-chloro-7-D-(2-phenyl-glycinamido)-3-cephem-4-carboxylic acid) on PAF, ADP, collagen, endotoxin, and thrombin-induced platelet aggregation were examined in vitro with the use of guinea pig platelet-rich plasma and washed platelets. PAF, even at concentrations lower than its minimum effective concentration, enhanced ADP- or endotoxin-induced platelet aggregation and prolonged the time to attain the maximum aggregation. PAF also enhanced collagen-induced platelet aggregation and shortened the lag time. Cefaclor (CCL) inhibited the PAF, ADP or thrombin induced platelet aggregation and shortened their maximum aggregation times at higher concentrations such as 300 micrograms/ml or more. CCL also inhibited the collagen-induced platelet aggregation and prolonged the lag time, but showed no effect on endotoxin-induced platelet aggregation. The effect of CCL was almost the same as that of latamoxef (LMOX). CCL and LMOX, however, showed no effect on cellular Ca2+ increase produced by PAF, ADP, or thrombin, suggesting that the inhibitory effect of CCL and LMOX on platelet aggregation is caused by the inhibition of fibrinogen binding to the glycoprotein IIb/IIIa complex.
authors.affiliation: Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kakushi
authors.forename: T
authors.initials: T
authors.lastname: Shike
authors.forename: Y
authors.initials: Y
authors.lastname: Hayasaki
authors.forename: T
authors.initials: T
authors.lastname: Matsubara
authors.forename: K
authors.initials: K
authors.lastname: Uchida
authors.forename: Y
authors.initials: Y
authors.lastname: Honma
authors.forename: K
authors.initials: K
authors.lastname: Kawasumi
authors.forename: Y
authors.initials: Y
authors.lastname: Takeuchi
mesh_terms: D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002433:Cefaclor / Q000009:adverse effects* / Q000494:pharmacology; D002506:Cephalexin / Q000031:analogs & derivatives*; D005340:Fibrinogen / Q000378:metabolism; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors; D013917:Thrombin / Q000037:antagonists & inhibitors
chemical_list: D008562:Membrane Glycoproteins; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D002433:Cefaclor; D005340:Fibrinogen; D013917:Thrombin; D002506:Cephalexin; D002118:Calcium